Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewsWire · Oct 7, 2026
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for ApprovalGlobeNewsWire · Aug 7, 2026Andina Acquisition Corp. III operates as a blank check company, specifically formed to pursue a business combination. Its primary objective is to engage in a transaction such as a merger, share swap, asset purchase, stock acquisition, financial restructuring, or corporate reorganization with one or more other entities.